FDA Clears MagVenture’s Device for the Treatment of Depression

Denmark–based MagVenture has achieved FDA marketing clearance for its MagVita TMS therapy system.

The device delivers transcranial magnetic stimulation (TMS) for patients not responding to medication.

The MagVita TMS delivers magnetic pulses to the part of the brain controlling mood. The rapid change in the magnetic field induces a current and excites neurons.

The treatment does not require anesthesia and is not to be confused with Electro Convulsive Therapy. — Cynthia Jessup